To disseminate the findings generated in VALUE-Dx by using various forms of communication and educational activities and publications at all levels of stakeholder platforms to promote their uptake and implementation in daily clinical practice and policy.
To develop innovative, effective ways to disseminate information for creating awareness of optimal diagnosis and prognosis of CA-ARTI to prevent unnecessary prescription and use of antibiotics, to improve coverage with antibiotics, and thus limit antibiotic resistance and associated health and socioeconomic impacts.
To develop and to tailor materials to support the adoption of CA ARTI-Dx in European community care settings.
https://value-dx.eu/wp-content/uploads/2019/09/VALUE-Dx_logo_white4.png4281226melanie.hostehttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngmelanie.hoste2020-01-10 14:15:252020-04-27 12:20:55Headway made for Point Prevalence Audit Survey in primary and long-term care settings
https://value-dx.eu/wp-content/uploads/2019/09/VALUE-Dx_logo_white4.png4281226Daniele Pazzolahttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2019-11-21 12:20:002020-01-10 14:18:44IMI article - Technology, not instinct, should guide antibiotic prescribing. A Q&A with Herman Goossens
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.